Quick Dispatch:
Your tirzepatide discontinuation weight regain study Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications | BMC Medicine orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide discontinuation weight regain study Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications | BMC Medicine ships.
Need Help?
Questions about tirzepatide discontinuation weight regain study Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications | BMC Medicine, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide discontinuation weight regain study Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications | BMC Medicine in your area.
What's been your experience as a patient or a clinician prescribing these? Across all the data combined, patients stopping semaglutide or tirzepatide regain an average of 9.69 kg (around 20 pounds) -of
22.99
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
25.40
Weight regain after cessation of medication for weight management: systematic review and meta-analysis
27.86
Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial
24.85
Many adults stop GLP-1 therapy within a year with low restart rates, analysis finds
23.31
In the SURMOUNT-4 trial, 82.5% of adults with obesity regained ≥25% of initial weight lost within one year of tirzepatide withdrawal; most showed reversal of cardiometabolic improvements. https://ja.ma/4qaMLfO
22.86
01200-X/asset/429e6fd1-61d1-402a-91a5-b2ec86b1b878/main.assets/gr2_lrg.jpg)
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
26.47
